Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Second-Generation Antidepressants for Treating Adult Depression—An Update

Slide: 19 of 28

Comparative Harms of Second-Generation Antidepressants

This portion (slides 19–25) of the presentation addresses whether the medications differ in safety or adverse effects. Of interest, as before, are the following: the selective serotonin reuptake inhibitors (SSRIs) citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline); the selective serotonin and norepinephrine reuptake inhibitors (SSNRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) desvenlafaxine, duloxetine, mirtazapine, and venlafaxine; and all other second-generation agents (bupropion, nefazodone, and trazodone). Data included outcomes from head-to-head trials, placebo-controlled trials, and observational studies assessing the comparative harms of second-generation antidepressants. Observational studies were also included when the sample size was larger than 1,000 and the study duration at least 3 months. Comparisons across different drugs should be made with caution, given differences in assessment and reporting of adverse events across trials.